The Adjunct Protocol: Measured Outcomes
The core evidence emerges from a review of five randomized clinical trials focusing on creatine as an adjunct treatment. The most cited protocol involved a daily dose of five grams of creatine monohydrate administered alongside a patient's existing antidepressant medication. This combination yielded statistically significant improvement in depressive symptoms compared to antidepressants alone over an eight-week observation period. A parallel finding noted enhanced efficacy when creatine was combined with cognitive behavioral therapy. The data frames creatine not as a standalone intervention, but as a potential amplifier of established therapies.
Mechanism: Fueling Neural Computation
The pivot from muscle to mood is grounded in bioenergetics. Creatine's primary role is the rapid regeneration of adenosine triphosphate (ATP), the cell's energy currency. In neurons, ATP availability is non-negotiable for sustaining high-frequency synaptic firing, neurotransmitter synthesis, and plasticity processes. A deficit in cerebral energy metabolism is increasingly implicated in the pathophysiology of depression. Supplemental creatine appears to buffer this deficit, providing a more resilient energy substrate for neural circuits governing mood and executive function. This directly links to the cognitive performance space: optimizing the brain's metabolic baseline is a prerequisite for sustained focus and mental resilience.
The Critical Variables for Assessment
While the data is mechanistically plausible, the signal requires calibration. The clinical trials are preliminary in scale and duration. Key unknowns include optimal dosing stratification for different depression phenotypes, long-term safety profiles in this specific population, and the precise latency to cognitive effect beyond mood scores. For the individual, this represents a potential low-risk, low-cost adjunct worth monitoring—but not a protocol to self-administer without clinical oversight. The measurable takeaway is the five-gram dose as a starting point for research, emphasizing that the intervention's value may lie in enhancing neuroplastic capacity and energetic resilience underpinning both mood and high-level cognition.